CagriSema Combination Outperforms Semaglutide Alone for Weight Loss in Meta-Analysis
The combination of cagrilintide (an amylin analog) with semaglutide (CagriSema) produced 9% greater weight loss than semaglutide alone, while cagrilintide by itself matched semaglutide's effectiveness with fewer vomiting side effects.
Quick Facts
What This Study Found
Key results from 3 RCTs with 430 participants:
**CagriSema vs semaglutide 2.4 mg (20-32 weeks):**
- Extra percentage weight loss: -9.07% (95% CI: -11.91 to -6.23)
- Extra absolute weight loss: -9.11 kg (95% CI: -12.84 to -5.39)
- GI adverse events and vomiting were significantly higher with CagriSema
**Cagrilintide 2.4 mg vs semaglutide/liraglutide (26-32 weeks):**
- Percentage weight loss: similar (MD -1.83%, non-significant, p=0.11)
- Absolute weight loss: similar (MD -1.88 kg, non-significant, p=0.12)
- Vomiting was significantly lower with cagrilintide
Treatment-emergent and serious adverse events were comparable across all groups.
Key Numbers
How They Did This
Systematic review and meta-analysis searching electronic databases for randomized controlled trials of cagrilintide alone or CagriSema in obese individuals compared to placebo or active comparators. Three RCTs with 430 participants were included. Primary outcomes were body weight changes; secondary outcomes included glycemia, lipids, and adverse events.
Why This Research Matters
CagriSema represents the next frontier in peptide-based obesity treatment — combining two different appetite-suppressing peptide pathways (GLP-1 and amylin) in a single weekly injection. The finding that it outperforms semaglutide alone by a substantial 9 kg is remarkable, as semaglutide was already considered the gold standard. This combination could set new benchmarks for non-surgical weight loss.
The Bigger Picture
The obesity treatment landscape is evolving rapidly from single-target peptide drugs to multi-peptide combinations. CagriSema (cagrilintide + semaglutide) represents a new approach: combining GLP-1 signaling with amylin signaling for additive appetite suppression. If Phase 3 trials confirm these results, CagriSema could become the most effective non-surgical weight loss treatment available, potentially achieving weight reductions previously only seen with bariatric surgery.
What This Study Doesn't Tell Us
Only 3 RCTs with 430 participants were available for analysis — a small evidence base for a meta-analysis. High heterogeneity (I² = 96-98%) across studies suggests inconsistency in effect sizes, limiting confidence in the pooled estimates. Study durations were relatively short (20-32 weeks), and long-term efficacy and safety remain unknown. The increased GI side effects with CagriSema may limit tolerability for some patients.
Questions This Raises
- ?Will CagriSema's superiority over semaglutide persist in larger Phase 3 trials with longer follow-up?
- ?Can the GI side effects of CagriSema be managed with slower dose titration without sacrificing efficacy?
- ?How does CagriSema compare to tirzepatide (the dual GLP-1/GIP agonist) for weight loss in head-to-head comparisons?
Trust & Context
- Key Stat:
- -9.11 kg more than semaglutide CagriSema (cagrilintide + semaglutide combination) produced dramatically more weight loss than semaglutide alone over 20-32 weeks
- Evidence Grade:
- This is a meta-analysis of 3 randomized controlled trials, providing moderate-quality evidence. The small number of trials, limited sample size (430 participants), and high heterogeneity are significant limitations. Phase 3 trials with larger cohorts will be needed to establish definitive efficacy and safety profiles.
- Study Age:
- Published in 2024, this meta-analysis captures early clinical trial data for CagriSema. Larger Phase 3 trials are underway and will provide more definitive evidence. This remains among the most current analyses of this emerging combination therapy.
- Original Title:
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.
- Published In:
- Indian journal of endocrinology and metabolism, 28(5), 436-444 (2024)
- Authors:
- Dutta, Deep(10), Nagendra, Lakshmi(7), Harish, B G, Sharma, Meha, Joshi, Ameya, Hathur, Basavanagowdappa, Kamrul-Hasan, Abm
- Database ID:
- RPEP-08129
Evidence Hierarchy
Frequently Asked Questions
What is cagrilintide and how does it differ from semaglutide?
Cagrilintide is a long-acting analog of amylin, a peptide hormone released alongside insulin that naturally reduces appetite and slows stomach emptying. Semaglutide mimics a different gut hormone (GLP-1). By combining both — targeting two separate appetite pathways — CagriSema produces greater weight loss than either drug alone. Think of it as attacking obesity from two different biological angles simultaneously.
When will CagriSema be available?
CagriSema is currently in Phase 3 clinical trials. Based on typical drug development timelines, it could potentially receive regulatory approval within the next few years if trials confirm the early positive results seen in this meta-analysis. Novo Nordisk (which also makes semaglutide/Wegovy) is developing CagriSema.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08129APA
Dutta, Deep; Nagendra, Lakshmi; Harish, B G; Sharma, Meha; Joshi, Ameya; Hathur, Basavanagowdappa; Kamrul-Hasan, Abm. (2024). Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.. Indian journal of endocrinology and metabolism, 28(5), 436-444. https://doi.org/10.4103/ijem.ijem_45_24
MLA
Dutta, Deep, et al. "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.." Indian journal of endocrinology and metabolism, 2024. https://doi.org/10.4103/ijem.ijem_45_24
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and Safety of Cagrilintide Alone and in Combination..." RPEP-08129. Retrieved from https://rethinkpeptides.com/research/dutta-2024-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.